T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems (NASDAQ:TTOO) has successfully defended a key patent for its direct-from-whole blood detection method in the European Union. The opposition, filed in May 2023 by bioMerieux and an undisclosed party, challenged T2 Biosystems' European Patent No. 3 443 124. This patent is important to the company's intellectual property portfolio for detecting pathogens directly from whole blood samples.
The European Patent Office's Opposition Division held a public hearing on September 19, 2024, ruling in favor of T2 Biosystems. This decision maintains the company's strong IP position in pathogen detection technology. John Sperzel, Chairman and CEO, expressed confidence in the broad scope of their IP portfolio and stated their intention to continue defending against future challenges while advancing their technology, commercial platform, and product pipeline.
T2 Biosystems (NASDAQ:TTOO) ha difeso con successo un brevetto chiave per il suo metodo di rilevamento diretto da sangue intero nell'Unione Europea. L'opposizione, presentata nel maggio 2023 da bioMerieux e da una parte non divulgata, ha contestato il Brevetto Europeo No. 3 443 124 di T2 Biosystems. Questo brevetto è importante per il portafoglio di proprietà intellettuale dell'azienda per il rilevamento di patogeni direttamente da campioni di sangue intero.
La Divisione di Opposizione dell'Ufficio Brevetti Europeo ha tenuto un'udienza pubblica il 19 settembre 2024, pronunciandosi a favore di T2 Biosystems. Questa decisione mantiene la forte posizione IP dell'azienda nella tecnologia di rilevamento dei patogeni. John Sperzel, Presidente e CEO, ha espresso fiducia nell'ampia portata del loro portafoglio IP e ha dichiarato l'intenzione di continuare a difendere contro sfide future mentre avanza la loro tecnologia, piattaforma commerciale e pipeline di prodotti.
T2 Biosystems (NASDAQ:TTOO) ha defendido con éxito una patente clave para su método de detección directa de sangre completa en la Unión Europea. La oposición, presentada en mayo de 2023 por bioMerieux y una parte no desvelada, impugnó la Patente Europea No. 3 443 124 de T2 Biosystems. Esta patente es importante para el portafolio de propiedad intelectual de la empresa en la detección de patógenos directamente de muestras de sangre completa.
La División de Oposición de la Oficina Europea de Patentes llevó a cabo una audiencia pública el 19 de septiembre de 2024, fallando a favor de T2 Biosystems. Esta decisión mantiene la sólida posición IP de la empresa en la tecnología de detección de patógenos. John Sperzel, Presidente y CEO, expresó confianza en el amplio alcance de su portafolio IP y declaró su intención de seguir defendiendo contra futuros desafíos mientras avanza su tecnología, plataforma comercial y línea de productos.
T2 바이오시스템즈(NASDAQ:TTOO)는 유럽연합에서 전혈 직접 검출 방법에 대한 핵심 특허를 성공적으로 방어했습니다. 2023년 5월, bioMerieux와 공개되지 않은 당사자가 제기한 이의신청은 T2 바이오시스템즈의 유럽 특허 번호 3 443 124에 도전했습니다. 이 특허는 전혈 샘플에서 직접적으로 병원체를 검출하는 회사의 지적 재산 포트폴리오에 중요합니다.
유럽특허청의 이의신청 부서는 2024년 9월 19일 공개 청문회를 열어 T2 바이오시스템즈에 유리한 판결을 내렸습니다. 이 결정은 병원체 검출 기술에서 회사의 강력한 IP 위치를 유지합니다. 존 스퍼젤(Jon Sperzel) 회장 겸 CEO는 그들의 IP 포트폴리오의 폭넓은 범위에 대한 확신을 표명했으며, 앞으로의 도전에 계속해서 방어하고, 기술, 상업 플랫폼 및 제품 파이프라인을 발전시키겠다는 의지를 밝혔습니다.
T2 Biosystems (NASDAQ:TTOO) a réussi à défendre un brevet clé pour sa méthode de détection directe à partir de sang entier au sein de l'Union Européenne. L'opposition, déposée en mai 2023 par bioMerieux et une partie non divulguée, a contesté le Brevet Européen No. 3 443 124 de T2 Biosystems. Ce brevet est essentiel pour le portefeuille de propriété intellectuelle de l'entreprise pour la détection des pathogènes directement à partir d'échantillons de sang entier.
La Division des Oppositions de l'Office Européen des Brevets a tenu une audience publique le 19 septembre 2024, rendant une décision en faveur de T2 Biosystems. Cette décision maintient la forte position IP de l'entreprise dans la technologie de détection des pathogènes. John Sperzel, Président et CEO, a exprimé sa confiance dans l'ampleur de leur portefeuille de propriété intellectuelle et a déclaré son intention de continuer à défendre contre de futurs défis tout en avançant dans leur technologie, leur plateforme commerciale et leur pipeline de produits.
T2 Biosystems (NASDAQ:TTOO) hat ein wichtiges Patent für seine Direktuntersuchungsmethode aus Vollblut in der Europäischen Union erfolgreich verteidigt. Der Einwand, der im Mai 2023 von bioMerieux und einer nicht genannten Partei eingereicht wurde, stellte das Europäische Patent Nr. 3 443 124 von T2 Biosystems in Frage. Dieses Patent ist wichtig für das geistige Eigentumsportfolio des Unternehmens zur direkten Erkennung von Krankheitserregern aus Vollblutproben.
Die Einwendungsabteilung des Europäischen Patentamtes hielt am 19. September 2024 eine öffentliche Anhörung ab und entschied zugunsten von T2 Biosystems. Diese Entscheidung stärkt die IP-Position des Unternehmens in der Technologie zur Erkennung von Krankheitserregern. John Sperzel, Vorsitzender und CEO, äußerte Vertrauen in den breiten Umfang ihres IP-Portfolios und erklärte die Absicht, zukünftige Herausforderungen weiterhin zu verteidigen, während sie ihre Technologie, Handelsplattform und Produktpipeline vorantreiben.
- Successfully defended a key patent for direct-from-whole blood pathogen detection method in the EU
- Maintained strong intellectual property position in pathogen detection technology
- Reinforced confidence in the broad scope of the company's IP portfolio
- None.
Insights
The successful defense of T2 Biosystems' patent in the EU is a significant legal victory for the company. This outcome strengthens their intellectual property position in the critical field of rapid sepsis detection. The ruling by the European Patent Office (EPO) affirms the validity and uniqueness of T2's direct-from-whole blood pathogen detection method.
From a legal perspective, this decision has several important implications:
- It protects T2 Biosystems from potential competitors using similar technology in the European market.
- It may deter future patent challenges, saving the company time and legal resources.
- It potentially increases the company's licensing opportunities and bargaining power in partnerships.
However, it's worth noting that bioMerieux and other undisclosed firms may still appeal this decision, which could lead to further legal proceedings. Investors should monitor for any announcements of appeals or new challenges to T2's patents in other jurisdictions.
T2 Biosystems' successful patent defense underscores the unique value of their direct-from-whole blood pathogen detection method in the medical diagnostics field. This technology is important for rapid sepsis detection, which can significantly improve patient outcomes in critical care settings.
The key advantages of this method include:
- Faster results compared to traditional blood culture methods
- Potential for earlier initiation of appropriate antibiotic therapy
- Reduced time to diagnosis, which is critical in sepsis cases
From a research perspective, this patent protection may encourage further investment in T2's technology platform, potentially leading to expanded applications and improved diagnostic capabilities. It also positions T2 Biosystems as a leader in sepsis diagnostics, which could attract collaborations with academic institutions and other industry partners for further advancements in this critical area of healthcare.
The successful defense of T2 Biosystems' patent in the EU is a positive development for the company's financial outlook. This outcome protects a key asset in their intellectual property portfolio, which is important for maintaining their competitive edge in the rapidly growing sepsis diagnostics market.
Financial implications include:
- Potential for increased market share in the EU, as competitors may be prevented from offering similar technologies
- Enhanced ability to attract strategic partnerships or licensing agreements, potentially leading to new revenue streams
- Reduced legal expenses in the short term, although appeals may still occur
Investors should note that while this is a positive development, T2 Biosystems still faces challenges, including the need to achieve profitability and expand market adoption of their technologies. The company's ability to leverage this patent protection into tangible financial results will be key to watch in the coming quarters.
LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.
The opposition was filed in May 2023 with the European Patent Office (EPO) by bioMerieux and a strawman representing other undisclosed firm(s) against T2 Biosystems’ granted European Patent No. 3 443 124, which relates to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample. This patent is part of T2 Biosystems’ intellectual property portfolio surrounding its proprietary direct-from-whole blood pathogen detection method. The Opposition Division of the EPO held a public hearing on September 19, 2024, and ruled such that T2 Biosystems’ strong IP position on the detection of pathogens directly from whole blood was maintained.
“This decision further supports the confidence we have in the broad scope conferred by our IP portfolio protecting our proprietary direct-from-whole blood pathogen detection method,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leading position, as we advance our technology, commercial platform, and product pipeline.”
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology and include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the T2Lyme™ Panel, and the expended T2Candida Panel to add the detection of Candida auris. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our patent portfolio, the potential of our direct-from-whole blood detection technology and products, statements regarding our patent portfolio, as well as statements that include the words “expect,” “may,” “should,” “anticipate,” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or SEC, on April 1, 2024, and other filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
What patent did T2 Biosystems (TTOO) successfully defend in the European Union?
Who filed the opposition against T2 Biosystems' (TTOO) patent in the European Union?
When did the European Patent Office hold the public hearing for T2 Biosystems' (TTOO) patent opposition?
What was the outcome of the patent opposition for T2 Biosystems (TTOO) in the European Union?
